The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-sense nucleotide-based compositions. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Anti-sense nucleotide-based compositions is a key innovation area in the pharmaceutical industry
Anti-sense oligonucleotides are small DNA or RNA pieces with the capability to interact with specific RNA molecules. The interaction hinders the ability of RNA to make a protein or conduct other functions. Anti-sense oligonucleotides can be utilised for inhibiting the production of proteins required for cell growth. They are being studied in the treatment of several types of cancers and other diseases.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 80+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-sense nucleotide-based compositions.
Key players in anti-sense nucleotide-based compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-sense nucleotide-based compositions
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Ionis Pharmaceuticals||1066||Unlock Company Profile|
|F. Hoffmann-La Roche||270||Unlock Company Profile|
|Alnylam Pharmaceuticals||242||Unlock Company Profile|
|Nippon Shinyaku||129||Unlock Company Profile|
|Regulus Therapeutics||125||Unlock Company Profile|
|Sanofi||117||Unlock Company Profile|
|Sarepta Therapeutics||103||Unlock Company Profile|
|Nogra Two||88||Unlock Company Profile|
|ProQR Therapeutics||75||Unlock Company Profile|
|Cold Spring Harbor Laboratory||75||Unlock Company Profile|
|Wave Life Sciences||73||Unlock Company Profile|
|Biogen||69||Unlock Company Profile|
|Centre National de la Recherche Scientifique||62||Unlock Company Profile|
|Novo Nordisk Foundation||58||Unlock Company Profile|
|Arbutus Biopharma||58||Unlock Company Profile|
|Bio-Path Holdings||54||Unlock Company Profile|
|Pfizer||46||Unlock Company Profile|
|Replicor||44||Unlock Company Profile|
|Daiichi Sankyo||41||Unlock Company Profile|
|OPKO Health||38||Unlock Company Profile|
|Scholar Rock Holding||33||Unlock Company Profile|
|Bristol-Myers Squibb||33||Unlock Company Profile|
|Biomarin Technologies||30||Unlock Company Profile|
|Neurovision Pharma||30||Unlock Company Profile|
|Merck & Co||29||Unlock Company Profile|
|Avidity Biosciences||28||Unlock Company Profile|
|Arrowhead Pharmaceuticals||27||Unlock Company Profile|
|Mitsubishi Chemical Group||25||Unlock Company Profile|
|Bonac||22||Unlock Company Profile|
|General Hospital||20||Unlock Company Profile|
|EdiGene||19||Unlock Company Profile|
|Silence Therapeutics||18||Unlock Company Profile|
|National Center of Neurology and Psychiatry||18||Unlock Company Profile|
|Kirin Holdings||17||Unlock Company Profile|
|Centre Leon Berard||16||Unlock Company Profile|
|Nissan Chemical||16||Unlock Company Profile|
|AptaBio Therapeutics||16||Unlock Company Profile|
|Institut de Myologie||16||Unlock Company Profile|
|Dynavax Technologies||16||Unlock Company Profile|
|Viridian Therapeutics||16||Unlock Company Profile|
|Massachusetts General Hospital||16||Unlock Company Profile|
|Nationwide Children's Hospital||16||Unlock Company Profile|
|City of Hope||15||Unlock Company Profile|
|Erasmus MC||15||Unlock Company Profile|
|Wings Therapeutics||14||Unlock Company Profile|
|Johnson & Johnson||14||Unlock Company Profile|
|Samjin Pharm||13||Unlock Company Profile|
|OPKO CURNA||13||Unlock Company Profile|
|Lipigon Pharmaceuticals||12||Unlock Company Profile|
|Danaher||12||Unlock Company Profile|
Source: GlobalData Patent Analytics
Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, is one of the leading patent filers in nucleic acid active pharmaceutical ingredient and focuses on the discovery and development of RNA-targeted drugs. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy, and Waylivra for familial chylomicronemia syndrome. Ionis develops products based on its proprietary antisense technology.
In terms of application diversity, OPKO CURNA is the top company, followed by Neurovision Pharma and Replicor. By means of geographic reach, Neurovision Pharma holds the top position. Pfizer and AptaBio Therapeutics are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.